Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Item
http://www.wikidata.org/entity/Q38929308
Polypharmacology in Precision Oncology: Current Applications and Future ProspectsC0818, a novel curcumin derivative, interacts with Hsp90 and inhibits Hsp90 ATPase activity.Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cellsMechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effectC1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro.
P2860

Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Item
http://www.wikidata.org/entity/Q38929308
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Dual inhibition of Bcr-Abl and ...... imatinib-resistant CML cells.
@en
type
label
Dual inhibition of Bcr-Abl and ...... imatinib-resistant CML cells.
@en
prefLabel
Dual inhibition of Bcr-Abl and ...... imatinib-resistant CML cells.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P356
P1433
P1476
Dual inhibition of Bcr-Abl and ...... imatinib-resistant CML cells.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-13-3317
P407
P433
P478
P577
P5875
P698